TPX2 and MKI67 have been recognized as prominent genes in gastric cancer [10, 60], with elevated TPX2 expression linked to tumor progression and poor survival outcomes, suggesting its potential role as a biomarker for adverse prognosis or a target for future therapeutic strategies in gastric cancer [60, 61]. This evidence concerns the gene TPX2 and gastric cancer.